|
시장보고서
상품코드
2075941
간세포암 치료제 시장 : 약제 클래스별, 치료법별, 투여 경로별, 지역별Hepatocellular Carcinoma Drugs Market, By Drug Class, By Treatment Modality, By Route of Administration, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
간세포암 치료제 시장은 2026년에 73억 6,000만 달러 규모에 이를 것으로 추정되며, 2033년까지 128억 7,000만 달러에 이를 것으로 예상되고 있습니다. 2026-2033년 CAGR 8.3%로 성장할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도 : | 2025년 | 시장 규모(2026년) : | 73억 6,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간 CAGR(2026-2033년) : | 8.30% | 시장 규모 예측(2033년) : | 128억 7,000만 달러 |
세계의 간세포암 치료제 시장에는 표적 치료제, 면역 치료제, 화학 요법제 및 이와 유사한 약물 군에 속하는 제품들이 포함됩니다. 이 약제들은 1차 치료, 2차 치료, 보조 요법에 폭넓게 적용되며, 경구 투여 및 정맥 내 투여를 통해 사용되고 있습니다. 조직이 성과, 효율성, 비용 대비 효과를 점점 더 중시함에 따라, 이러한 부문에서의 채용은 꾸준히 확대되고 있습니다.
시장 역학 :
경구 투여 및 정맥 내 투여에 대한 수요 증가, 효율성과 신뢰성 향상의 필요성, 그리고 지속적인 제품 혁신이 전 세계 간세포암 치료제 시장의 성장을 견인할 것으로 예상되는 주요 요인입니다. 1차 치료 및 2차 치료에서의 적용 확대가 이러한 추세를 더욱 강화하고 있습니다.
예를 들어, 시장에 진출한 각 기업은 1차 치료 용도로 설계된 첨단 솔루션을 도입하고 있습니다. 또한, 지속적인 기술 발전과 전략적 투자를 통해 예측 기간 동안 시장에 진출한 기업들에게 새로운 성장 기회가 창출될 것으로 전망됩니다.
본 조사의 주요 특징 :
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 시장 성장 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 지표를 바탕으로 세계 간세포암 치료제 시장의 주요 기업 프로파일을 소개했습니다.
- 본 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 이 책 '세계의 간세포암 치료제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 세계의 간세포암 치료제 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적 및 전제조건
제2장 시장 개요
제3장 시장 역학, 규제 및 동향 분석
제4장 간세포암 치료제 시장 : 약제 클래스별(2026-2033년)
제5장 간세포암 치료제 시장 : 치료법별(2026-2033년)
제6장 간세포암 치료제 시장 : 투여 경로별(2026-2033년)
제7장 간세포암 치료제 시장 : 지역별(2026-2033년)
제1장 경쟁 구도
제2장 섹션
AJY 26.07.09Hepatocellular Carcinoma Drugs Market is estimated to be valued at USD 7.36 billion in 2026 and is expected to reach USD 12.87 billion by 2033, growing at a compound annual growth rate (CAGR) of 8.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 7.36 billion |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.30% | 2033 Value Projection: | USD 12.87 billion |
The global hepatocellular carcinoma drugs market includes offerings that span Targeted Therapies, Immunotherapy, and Chemotherapy, and similar drug class categories. These are applied across First-line Treatment, Second-line Treatment, and Adjuvant Therapy and adopted by Oral, and Intravenous. As organizations increasingly prioritize performance, efficiency, and cost-effectiveness, adoption across these segments continues to grow steadily.
Market Dynamics:
Increasing demand from Oral, and Intravenous, the need for improved efficiency and reliability, and ongoing product innovation are major factors expected to drive growth of the global hepatocellular carcinoma drugs market. Broader adoption across First-line Treatment, and Second-line Treatment is reinforcing this momentum.
For instance, market players are introducing advanced solutions designed for First-line Treatment use cases. Moreover, continued technological advancement and strategic investment are expected to create new growth opportunities for market players over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global hepatocellular carcinoma drugs market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Bayer AG, Bristol-Myers Squibb, Eisai Co, Ltd., F. Hoffmann-La Roche AG, Novartis AG, Pfizer Inc., Merck & Co, Inc., AstraZeneca PLC, Sanofi S.A., Johnson & Johnson, Taiho Pharmaceutical Co, Ltd., Exelixis, Inc., and Ipsen S.A, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global hepatocellular carcinoma drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global hepatocellular carcinoma drugs market.
Detailed Segmentation:
- Global Hepatocellular Carcinoma Drugs Market, By Drug Class (Revenue, USD Bn, 2021 - 2033)
- Targeted Therapies
- Immunotherapy
- Chemotherapy
- Combination Therapy
- Others
- Global Hepatocellular Carcinoma Drugs Market, By Treatment Modality (Revenue, USD Bn, 2021 - 2033)
- First-line Treatment
- Second-line Treatment
- Adjuvant Therapy
- Supportive Care
- Others
- Global Hepatocellular Carcinoma Drugs Market, By Route of Administration (Revenue, USD Bn, 2021 - 2033)
- Oral
- Intravenous
- Subcutaneous
- Others
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Bayer AG*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Bristol-Myers Squibb
- Eisai Co, Ltd.
- F. Hoffmann-La Roche AG
- Novartis AG
- Pfizer Inc.
- Merck & Co, Inc.
- AstraZeneca PLC
- Sanofi S.A.
- Johnson & Johnson
- Taiho Pharmaceutical Co, Ltd.
- Exelixis, Inc.
- Ipsen S.A
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Preview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Treatment Modality
- Market Snapshot, By Route of Administration
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Market Opportunities
- Impact Analysis
- Recent Product Launches
- Epidemiology
- Merger, Acquisition, and Collaboration
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Partnership Scenario
- Brand and Pricing Analysis
- Distributors Landscape
- Porters Analysis
- Technological Advancements
- Key Developments
- Market Trend
- Future Prospective
- Top Market Players by Revenue
4. Hepatocellular Carcinoma Drugs Market By Drug Class, 2026-2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Targeted Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Immunotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Chemotherapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Combination Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
5. Hepatocellular Carcinoma Drugs Market By Treatment Modality, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- First Line Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Second Line Treatment
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Adjuvant Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Supportive Care
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
6. Hepatocellular Carcinoma Drugs Market By Route of Administration, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Subcutaneous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2026 - 2033, (US$ Billion)
7. Hepatocellular Carcinoma Drugs Market By Region, 2026 - 2033, (US$ Billion)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Benelux
- Denmark
- Norway
- Sweden
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- China
- Taiwan
- India
- Japan
- Indonesia
- Malaysia
- Philippines
- Singapore
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Modality, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2026 - 2033, (US$ Billion)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2026 - 2033, (US$ Billion)
- Bahrain
- Kuwait
- Oman
- Qatar
- Saudi Arabia
- UAE
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of the Middle East
1. Competitive Landscape
- Bayer AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Eisai Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- F. Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Ipsen S.A
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Taiho Pharmaceutical Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
- Exelixis, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Market Strategies
2. Section
- Research Methodology
- About Us
